What the Offseason Bought, and What It Didn't

The Blues spent the summer remaking their forward group. McMichael got six years and $40.5 million. McTavish came over from Anaheim. Dillon Dube won a roster spot. The organizational message was clear: this team could score, and it was going to commit to that identity. Three games into the new season, Alexy Toropchenko is out at least six weeks with an apparent shoulder injury, and the forward depth that all that spending was supposed to create is already being stress-tested in ways that expose how thin the margin actually was.

Here is the number that matters: Toropchenko went down in the first period of the opener in Dallas — the same game St. Louis won 4-0, the one that briefly made the offseason look like it worked. His absence doesn't gut the top six. It hollows out the bottom half of the roster, the part that was never the focus of the summer's ambitions. The Blues opened the year with Zach Dean and Dillon Dube winning the 13th and 14th forward slots. Sundqvist, Walker, and Finley all cleared waivers and were assigned to Springfield. Nobody wanted them. That was the depth pool the front office built below the investment layer, and now it has to absorb a six-week absence from one of the few forwards with meaningful NHL mileage at that level.

The offseason logic was sound on paper. Robert Thomas — 38 points in 45 games last year, the team's most reliable producer — needed better players around him, and management went and got them. What the spending didn't address was the connective tissue: the forwards who play 12 to 14 minutes a night, kill penalties, absorb physical minutes, and keep the lineup functional when someone above them gets hurt. That tier was an afterthought. Sundqvist was supposed to be part of it, but he's in Springfield. What's left at that level is thin enough that Toropchenko's absence registers immediately on the depth chart rather than being absorbed quietly.

My read is that this was always the structural flaw in the offseason plan. The Blues made a forward-group argument with their dollars — McMichael's contract, the McTavish acquisition — while the actual competitive problem from last season was defensive. They allowed 3.1 goals per game over the final ten games of 2026 even while scoring at a 4.0-goal clip. That paradox didn't get solved. What got solved, partially, was the top-end forward question. The depth question got a Dillon Dube and a prayer. Now the prayer is being tested in week one.

What makes this harder to wave away is the injury context surrounding it. Mailloux is eight weeks out with hand surgery. Tucker is on injured reserve. Brandon Carlo, brought in specifically to stabilize the blue line, still has no clear return timeline. The Blues are managing multiple absences simultaneously across both lines and the blue line, and the forward depth chart behind Thomas now runs through a group of players who were, just two weeks ago, fighting to stay on the roster at all. The offseason spending bought real talent at the top. It did not buy resilience below it, and resilience is what October requires.